What is JNJ's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 652.48B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for JNJ?

P/E (TTM) is 40.66 and 52-week range is $184.66 to $281.07 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s JNJ figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for JNJ?

The company profile lists revenue (TTM) near $97.66B, net income (TTM) near $15.82B, EPS (TTM) near $6.59 when available from the market-data feed. Figures are informational and may lag live markets.

Does JNJ show a dividend on Chartloom?

The overview lists dividend per share (TTM) near $5.24, yield near 1.93%, ex-dividend date Nov 24, 2026 when those figures are present. Dividend history is compiled from vendor data, not a distribution notice.

Where is Johnson & Johnson based, and what identifiers does Chartloom list?

The company context section lists headquarters in New Brunswick, New Jersey, US, 2.41B shares outstanding, ISIN US4781601046 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Johnson & Johnson

$JNJ

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 138,200 full-time employees. Its segments include Innovative Medicine and MedTech. The Innovative Medicine segment focuses on various therapeutic areas, oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases and cardiovascular and metabolism. Its products include CARVYKTI (ciltacabtagene autoleucel), DARZALEX (daratumumab), DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), ERLEADA (apalutamide), among others. The MedTech segment develops and manufactures a broad portfolio of products used in cardiovascular, orthopedics, surgery, and vision supporting physicians, hospitals, eye care professionals and healthcare systems across a range of acute and elective procedures. The Cardiovascular portfolio includes electrophysiology products. The company is also focused on proprietary Firelink degrader antibody conjugate platform.

Employees

138,200

Website

www.jnj.com/

IPO

1944-09-25

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NEW YORK STOCK EXCHANGE, INC.

ISIN

US4781601046

Headquarters

New Brunswick, New Jersey, US

Shares outstanding

2.41B

NAICS sector

Manufacturing

Institutional ownership

76.75%

Browse other companiesFree AI scores and summaries for more stocks